Press Release

Press Release - Q2FY27 - Revenue from operations Rs 79.1bn +29% y-y; EBITDA Rs 18.9bn -6% y-y; EBITDA margin 24.0%; PAT Rs 9.3bn -27% y-y - Branded sales in US rose to 16%, specialty portfolio expanding - Saroglitazar US launch pending approval, first indigenously discovered NCE - India formulations up 18% y-y; North America formulations up 21% y-y - Consumer wellness revenue up 76% y-y; MedTech up 47% y-y - Capex Rs 4.7bn in Q2; net debt to equity 0.19x, net debt to EBITDA 0.62x - USFDA inspections concluded with observations; approvals received for transdermal patch - Phase III Saroglitazar data presented; Phase IIb MASH trial completed - Pembrolizumab biosimilar BLA accepted for US review - Licensing agreement for Alvelestat in late-stage development